<DOC>
	<DOCNO>NCT00031889</DOCNO>
	<brief_summary>RATIONALE : Androgens stimulate growth prostate cancer cell . Hormone therapy use exemestane plus bicalutamide may fight prostate cancer reduce production androgen . It yet know exemestane effective without bicalutamide treat prostate cancer . PURPOSE : Randomized phase II trial study effectiveness exemestane without bicalutamide treat patient stage IV prostate cancer previously treat hormone therapy surgery .</brief_summary>
	<brief_title>Exemestane With Without Bicalutamide Treating Patients With Stage IV Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Compare efficacy tolerability exemestane without bicalutamide second-line therapy failure androgen suppression ( luteinizing hormone-releasing hormone agonist orchiectomy ) patient stage IV prostate cancer . - Determine potential antagonistic effect weak androgen action exemestane combine bicalutamide patient . - Compare quality life ( QOL ) patient treat regimen . - Correlate prostate-specific antigen response data QOL , include score pain intensity analgesic consumption , patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord performance status ( 0 vs 1-2 ) , pain ( none mild v moderate severe ) , participate center . Patients randomize 1 2 treatment arm . - Arm I : Patients receive oral exemestane daily . - Arm II : Patients receive exemestane arm I oral bicalutamide daily . Treatment arm continue every 4 week minimum 2 course absence disease progression unacceptable toxicity . Quality life pain assessed baseline , day 1 course 2 subsequent course , disease progression treatment failure ( applicable ) . Patients follow monthly disease progression . PROJECTED ACCRUAL : A total 20-62 patient ( 10-31 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm stage IV adenocarcinoma prostate Documented disease progression base prostatespecific antigen ( PSA ) progression firstline androgen suppression ( luteinizing hormonereleasing hormone agonist orchiectomy ) PSA progression define follow : Interval least 1 week reference value ( time point value 1 ) next PSA level ( time point value 2 ) PSA time point value 3 great PSA time point value 2 OR PSA time point value 3 great PSA time point value 2 , PSA time point value 4 great PSA time point value 2 PSA least 5 ng/mL Must continue primary androgen suppression prior surgical castration No know leptomeningeal brain metastasis PATIENT CHARACTERISTICS : Age : 18 Performance status : WHO 02 Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm^3 Neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9 g/dL Hepatic : Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 2.5 time ULN Renal : Creatinine great 1.5 time ULN Other : No acute concurrent severe infection No concurrent significant disease would preclude study therapy No malignancy within past 5 year except curatively treat basal cell squamous cell skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : No prior antibody gene therapy Chemotherapy : No prior cytostatic agent Endocrine therapy : See Disease Characteristics No prior estramustine No prior antiandrogens ( e.g. , bicalutamide ) No concurrent estrogencontaining medicine Radiotherapy : More 4 week since prior radiotherapy No concurrent radiotherapy 1 field Surgery : See Disease Characteristics Other : At least 4 week since prior investigational drug</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>